Search Results for "cancer"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for cancer. Results 301 to 310 of 599 total matches.
Vimseltinib (Romvimza) for Tenosynovial Giant Cell Tumor (online only)
The Medical Letter on Drugs and Therapeutics • Apr 14, 2025 (Issue 1726)
Interactions: Concurrent use of vimseltinib and drugs
that are substrates of P-glycoprotein, breast cancer ...
Vimseltinib (Romvimza – Deciphera), an oral kinase
inhibitor, has been approved by the FDA for treatment
of symptomatic tenosynovial giant cell tumor in adults
for whom surgical resection would cause worsening
functional limitation or severe morbidity. The kinase
inhibitor pexidartinib (Turalio) was approved for a
similar indication in 2019.
Med Lett Drugs Ther. 2025 Apr 14;67(1726):e66-7 doi:10.58347/tml.2025.1726h | Show Introduction Hide Introduction
Drugs for Common Eye Disorders
The Medical Letter on Drugs and Therapeutics • Dec 02, 2019 (Issue 1586)
was that lung
cancers occurred more frequently in patients who
received beta carotene than in those who did ...
This issue includes reviews of drugs for glaucoma,
age-related macular degeneration (AMD), bacterial
conjunctivitis, and dry eye disease. Allergic conjunctivitis
is reviewed in a separate issue.
Pentostatin and 2-Chlorodeoxyadenosine for Hairy-Cell Leukemia
The Medical Letter on Drugs and Therapeutics • Sep 18, 1992 (Issue 879)
(JB Johnston et al, J Natl Cancer Inst, 80:765, 1988; EH
Kraut et al, J Clin Oncol, 7:168, 1989; AD ...
Pentostatin (2'-deoxycoformycin; DCF; - Parke-Davis), a purine analog, was recently approved by the US Food and Drug Administration (FDA) for treatment of hairy-cell leukemia resistant to interferon alfa (Intron A; Roferon-A). is a rare (500 cases/year in the USA) form of chronic lymphocytic leukemia. Acutely ill patients may respond rapidly to interferon, but the drug is rarely curative. Another purine analog, 2-chlorodeoxyadenosine (CdA; Leustatin - Ortho Biotech), may also be approved soon for treatment of hairy-cell leukemia (JD Piro, Blood, 79:843, 1992). Fludarabine (Fludara...
Over-the-counter H2-Receptor Antagonists for Heartburn
The Medical Letter on Drugs and Therapeutics • Oct 27, 1995 (Issue 960)
such as gastric cancer (M Feldman, Arch Intern Med, 153:2415, 1993).
DRUG INTERACTIONS — Cimetidine interacts ...
Patients may be asking their physicians about use of histamine H2-receptor antagonists for treatment and prevention of heartburn. Cimetidine and famotidine have recently been released for over-the-counter sale and are being heavily advertised on television and in the print media.
Rituximab for Non-Hodgkins Lymphoma
The Medical Letter on Drugs and Therapeutics • Jun 19, 1998 (Issue 1029)
, Cancer Biother Radiopharmaceuticals, 12:177, 1997).
PHARMACOKINETICS — The half-life of rituximab ...
Rituximab (Rituxan - IDEC Pharmaceutical/Genentech), a monoclonal antibody, has been approved by the FDA for treatment of low-grade B-cell non-Hodgkin's lymphoma. Most low-grade lymphomas are B-cell lymphomas.
A New Conjugated Estrogen
The Medical Letter on Drugs and Therapeutics • Jul 30, 1999 (Issue 1058)
or uterine cancer, women with undiagnosed vaginal bleeding, active thrombophlebitis or thromboembolic ...
A new synthetic conjugated estrogen product (Cenestin - Duramed) was recently approved by the US Food and Drug Administration for treatment of vasomotor symptoms due to estrogen deficiency.
Carfilzomib (Kyprolis) for Multiple Myeloma
The Medical Letter on Drugs and Therapeutics • Dec 24, 2012 (Issue 1406)
bortezomib resistance. J Natl Cancer Inst 2011; 103:1007.
4. SD Demo et al. Antitumor activity of PR-171 ...
The FDA has approved carfilzomib (Kyprolis – Onyx),
a proteasome inhibitor, for intravenous treatment of
refractory multiple myeloma. Bortezomib (Velcade)
was the first proteasome inhibitor to be approved for
this indication.
In Brief: Dabrafenib (Tafinlar) and Trametinib (Mekinist) for Glioma (online only)
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023 (Issue 1674)
and involvement of lymph nodes following complete
resection
▶ Metastatic non-small cell lung cancer (NSCLC ...
The oral kinase inhibitors dabrafenib (Tafinlar –
GSK) and trametinib (Mekinist – Novartis) have been
approved by the FDA for use together for a sixth
indication: treatment of low-grade glioma (LGG)
with a BRAF V600E mutation in patients ≥1 years old
who require systemic therapy. This combination is
the first systemic therapy to be approved in the US
for first-line treatment of LGG with a BRAF V600E
mutation in pediatric patients. The FDA also approved
new oral formulations of both drugs for patients
who are unable to swallow dabrafenib capsules or
trametinib...
Med Lett Drugs Ther. 2023 Apr 17;65(1674):e75-6 doi:10.58347/tml.2023.1674i | Show Introduction Hide Introduction
In Brief: Azmiro — A Single-Dose Injectable Formulation of Testosterone Cypionate
The Medical Letter on Drugs and Therapeutics • Mar 17, 2025 (Issue 1724)
(PSA) levels;
whether it increases the risk of prostate cancer is
unclear.3 Like other testosterone ...
The FDA has approved Azmiro (Azurity), the first
injectable formulation of testosterone cypionate to
become available in single-dose vials and prefilled
syringes for treatment of males with conditions
associated with a deficiency or absence of endogenous
testosterone. Injectable testosterone cypionate has
been available in multidose vials (Depo-Testosterone,
and generics) for many years. Testosterone enanthate
(Xyosted) is available in prefilled autoinjectors for use
in adult men. No testosterone products are approved
for treatment of low testosterone levels due solely
to aging. All...
Med Lett Drugs Ther. 2025 Mar 17;67(1724):44-5 doi:10.58347/tml.2025.1724b | Show Introduction Hide Introduction
Oral Oxymorphone (Opana)
The Medical Letter on Drugs and Therapeutics • Jan 01, 2007 (Issue 1251)
in relieving osteoarthritis and chronic low back
pain, and was effective in relieving cancer pain in
patients ...
Oxymorphone hydrochloride, a semi-synthetic opioid agonist, has been available for many years in the US as Numorphan (Endo) for parenteral use and as a rectal suppository. Now it has been approved by the FDA for oral administration as an immediate-release (IR) tablet (Opana) for treatment of moderate to severe acute pain, and as an extended-release tablet (Opana ER) for treatment of moderate to severe pain in patients requiring continuous opioid treatment for an extended period of time.